$3.57
1.13% day before yesterday
NYSE, Sep 12, 10:00 pm CET
ISIN
US20454B1044
Symbol
CMPX

Compass Therapeutics Stock price

$3.57
+0.40 12.62% 1M
+1.06 42.23% 6M
+2.12 146.21% YTD
+2.03 131.82% 1Y
+0.59 19.80% 3Y
-4.93 58.00% 5Y
-4.93 58.00% 10Y
-0.53 12.93% 20Y
NYSE, Closing price Fri, Sep 12 2025
+0.04 1.13%
ISIN
US20454B1044
Symbol
CMPX
Industry

Key metrics

Basic
Market capitalization
$612.5m
Enterprise Value
$511.6m
Net debt
positive
Cash
$101.0m
Shares outstanding
138.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
6.6
Financial Health
Equity Ratio
89.2%
Return on Equity
-39.4%
ROCE
-48.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-48.9m | $-81.4m
EBIT
$-49.9m | $-82.7m
Net Income
$-45.4m | $-75.3m
Free Cash Flow
$-45.3m
Growth (TTM | estimate)
Revenue
-100.0% | -100.0%
EBITDA
10.3% | -45.2%
EBIT
9.5% | -46.1%
Net Income
3.9% | -52.5%
Free Cash Flow
-5.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.3
FCF per Share
$-0.3
Short interest
9.7%
Employees
35
Rev per Employee
$20.0k
Show more

Is Compass Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Compass Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Compass Therapeutics forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Compass Therapeutics forecast:

Buy
94%
Hold
6%

Financial data from Compass Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
16% 16%
-
- Research and Development Expense 38 38
9% 9%
-
-49 -49
10% 10%
-
- Depreciation and Amortization 1.01 1.01
58% 58%
-
EBIT (Operating Income) EBIT -50 -50
10% 10%
-
Net Profit -45 -45
4% 4%
-

In millions USD.

Don't miss a Thing! We will send you all news about Compass Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Compass Therapeutics Stock News

Neutral
Seeking Alpha
4 days ago
Compass Therapeutics, Inc. (NASDAQ:CMPX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 5:35 PM EDT Company Participants Thomas Schuetz - CEO & Vice Chairman Barry Shin - Chief Financial Officer Conference Call Participants Kelly McCarthy Presentation Kelly McCarthy Good afternoon, everyone. This is Kelly McCarthy from the Morgan Stanley Healthcare team, and it's gre...
Neutral
GlobeNewsWire
19 days ago
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September.
Positive
Seeking Alpha
about one month ago
Compass Therapeutics' pipeline shows promise, especially with tovecimig's positive phase 2 results in biliary tract cancers and upcoming basket study plans. CTX-8371's early signals in NSCLC and TNBC support dose expansion, with detailed phase 1 data expected in Q4 2025. Preclinical candidate CTX-10726 demonstrates potential superiority to competitors, with an IND submission targeted for Q4 2025.
More Compass Therapeutics News

Company Profile

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Head office United States
CEO Thomas Schuetz
Employees 35
Founded 2014
Website www.compasstherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today